Citadel Advisors’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-100
Closed -$1.8K 14304
2024
Q1
$1.8K Sell
100
-100
-50% -$1.81K ﹤0.01% 14079
2023
Q4
$3.39K Hold
200
﹤0.01% 13602
2023
Q3
$3.97K Buy
+200
New +$3.79K ﹤0.01% 13529

Other funds holding BTAL

Citadel Advisors's BTAL Position: Q4 2025 in Review

Citadel Advisors sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q4 2025, closing a stake of 33,821 shares — an estimated $538K sold.

Citadel Advisors first reported a position in BTAL in Q2 2016 and held it in 13 quarters. The position peaked at $8.28M in Q3 2020. 81 funds tracked by Wall St. Rank hold BTAL as of Q4 2025.

  • Citadel Advisors reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 33,821 AGF US Market Neutral Anti-Beta Fund shares in Q4 2025, an estimated $538K.
  • Citadel Advisors first reported a position in AGF US Market Neutral Anti-Beta Fund in Q2 2016 and held it in 13 quarters.
  • Citadel Advisors's AGF US Market Neutral Anti-Beta Fund position peaked at $8.28M in Q3 2020.
  • 81 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.